Physical activity is associated with reduced mortality in patients with breast and colon cancer, according to a study published in the Journal of the National Cancer Institute.[1] So far, there is insufficient evidence to draw the same conclusion with... Continue Reading
The U.S. Food and Drug Administration (FDA) has performed a systematic review of the long-term safety and efficacy of bisphosphonates and has recommended caution and updated labeling, but stopped short of imposing a regulatory restriction on the duration... Continue Reading
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading
Women are 30 percent more likely to survive melanoma than men, according to the results of a study published in the Journal of Clinical Oncology.[1] Melanoma is a deadly type of skin cancer that arises from melanocytes, which are cells located in the... Continue Reading
Patients with newly diagnosed multiple myeloma who receive Revlimid® (lenalidomide) may be at an increased risk of developing new cancers, according to a safety announcement released by the U.S. Food and Drug Administration (FDA). Revlimid is an oral... Continue Reading
Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer... Continue Reading
The final analysis of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) indicated that vitamin E increased the risk of developing prostate cancer in otherwise healthy men by 17% when compared to placebo. The results of the study were published... Continue Reading